Advertisement

Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven

Hugo J.A. Adams and Thomas C. Kwee
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.